DulaglutideGLP-1 PeptideSafety Rating 8/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors
Overview
About Dulaglutide
Mechanism of action
GLP-1 receptor agonist fused to IgG4 Fc; long-acting GLP-1R activation; improves glycemic control, reduces appetite, cardiovascular protective effects. Once-weekly.
Safety profile
Nausea, diarrhea, vomiting, abdominal pain; less weight loss than semaglutide; pancreatitis risk; thyroid tumor risk. · Extensive clinical data; GI side effects manageable; thyroid C-cell warning (animal only)
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Dulaglutide below your target.
Related pages
More on Dulaglutide
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- The REWIND cardiovascular outcomes trial (Lancet 2019, n=9,901, median follow-up 5.4 years) showed once-weekly dulaglutide reduced the primary MACE composite endpoint by 12% (HR 0.88, p=0.026) in T2D patients, including a notably large proportion with no prior cardiovascular disease — supporting cardioprotection even in lower-risk populations.
- The AWARD clinical development program (six Phase 3 trials) established dulaglutide 1.5 mg as superior to exenatide, insulin glargine, metformin, and sitagliptin comparators on HbA1c reduction, with AWARD-1 demonstrating -1.51% HbA1c vs -0.99% for exenatide at 52 weeks.